Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy for myocardial infarction.

A D Guerci1

  • 1Johns Hopkins Medical Institutions, Baltimore.

Maryland Medical Journal (Baltimore, Md. : 1985)
|April 1, 1990
PubMed
Summary

Thrombolytic therapy can reduce infarct size and mortality. Patients benefit most when treatment is early, the ischemic region is large, and hemorrhage risk is low.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study.

Arteriosclerosis, thrombosis, and vascular biology·2001
Same author

Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification.

Controlled clinical trials·2001
Same author

Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.

Circulation·2001
Same author

Potential use of Ca++ scanning to determine the need for and intensity of lipid-lowering therapy in asymptomatic adults.

Current cardiology reports·2001
Same author

Prediction of coronary events with electron beam computed tomography.

Journal of the American College of Cardiology·2000
Same author

Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.

Circulation·2000

Area of Science:

  • Cardiology
  • Emergency Medicine

Background:

  • Thrombolytic therapy is a key intervention for acute ischemic events.
  • Effective treatment hinges on timely administration and patient selection.

Purpose of the Study:

  • To outline the critical factors influencing the benefit of thrombolytic therapy.
  • To guide clinicians in risk-benefit assessment for thrombolytic treatment.

Main Methods:

  • Clinical review of thrombolytic therapy protocols.
  • Analysis of patient outcomes based on treatment timing and risk factors.

Main Results:

  • Early intervention is crucial for salvaging ischemic myocardium.
  • Patient selection based on infarct size and hemorrhage risk impacts outcomes.

Conclusions:

  • Thrombolytic therapy offers significant benefits in reducing infarct size and mortality.
  • Careful consideration of infarct size, treatment timing, and hemorrhage risk optimizes patient outcomes.

Related Experiment Videos